GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MannKind Corp (NAS:MNKD) » Definitions » Piotroski F-Score

MannKind (MannKind) Piotroski F-Score

: 7 (As of Today)
View and export this data going back to 2004. Start your Free Trial

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

MannKind has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for MannKind's Piotroski F-Score or its related term are showing as below:

MNKD' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 4   Max: 7
Current: 7

During the past 13 years, the highest Piotroski F-Score of MannKind was 7. The lowest was 1. And the median was 4.


MannKind Piotroski F-Score Historical Data

The historical data trend for MannKind's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MannKind Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 4.00 3.00 3.00 7.00

MannKind Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 5.00 5.00 6.00 7.00

Competitive Comparison

For the Biotechnology subindustry, MannKind's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MannKind Piotroski F-Score Distribution

For the Biotechnology industry and Healthcare sector, MannKind's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where MannKind's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -9.795 + -5.265 + 1.721 + 1.401 = $-11.9 Mil.
Cash Flow from Operations was 1.156 + 2.596 + 8.664 + 21.678 = $34.1 Mil.
Revenue was 40.626 + 48.611 + 51.253 + 58.472 = $199.0 Mil.
Gross Profit was 24.413 + 34.374 + 36.999 + 40.405 = $136.2 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(295.282 + 298.137 + 313.422 + 320.328 + 475.198) / 5 = $340.4734 Mil.
Total Assets at the begining of this year (Dec22) was $295.3 Mil.
Long-Term Debt & Capital Lease Obligation was $252.6 Mil.
Total Current Assets was $373.4 Mil.
Total Current Liabilities was $104.1 Mil.
Net Income was -25.998 + -29.023 + -14.432 + -17.947 = $-87.4 Mil.

Revenue was 11.992 + 18.894 + 32.825 + 36.059 = $99.8 Mil.
Gross Profit was 0.994 + 5.979 + 15.365 + 19.935 = $42.3 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(321.161 + 308.318 + 285.797 + 293.837 + 295.282) / 5 = $300.879 Mil.
Total Assets at the begining of last year (Dec21) was $321.2 Mil.
Long-Term Debt & Capital Lease Obligation was $278.8 Mil.
Total Current Assets was $234.9 Mil.
Total Current Liabilities was $67.3 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

MannKind's current Net Income (TTM) was -11.9. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

MannKind's current Cash Flow from Operations (TTM) was 34.1. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-11.938/295.282
=-0.04042915

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-87.4/321.161
=-0.27213765

MannKind's return on assets of this year was -0.04042915. MannKind's return on assets of last year was -0.27213765. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

MannKind's current Net Income (TTM) was -11.9. MannKind's current Cash Flow from Operations (TTM) was 34.1. ==> 34.1 > -11.9 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=252.624/340.4734
=0.74197867

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=278.833/300.879
=0.92672802

MannKind's gearing of this year was 0.74197867. MannKind's gearing of last year was 0.92672802. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=373.393/104.125
=3.5860072

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=234.896/67.296
=3.49048978

MannKind's current ratio of this year was 3.5860072. MannKind's current ratio of last year was 3.49048978. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

MannKind's number of shares in issue this year was 269.678. MannKind's number of shares in issue last year was 263.446. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=136.191/198.962
=0.68450759

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=42.273/99.77
=0.42370452

MannKind's gross margin of this year was 0.68450759. MannKind's gross margin of last year was 0.42370452. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=198.962/295.282
=0.67380335

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=99.77/321.161
=0.31065416

MannKind's asset turnover of this year was 0.67380335. MannKind's asset turnover of last year was 0.31065416. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+1+1+1+1+1+0+1+1
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

MannKind has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

MannKind  (NAS:MNKD) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


MannKind Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of MannKind's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


MannKind (MannKind) Business Description

Traded in Other Exchanges
Address
1 Casper Street, Danbury, CT, USA, 06810
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
Executives
Michael Castagna officer: Chief Commercial Officer 25134 RYE CANYON LOOP, SUITE 300, VALENCIA CA 91355
David Thomson officer: VP & Assoc General Counsel 28903 NORTH AVENUE PAINE, VALENCIA CA 91355
Steven B. Binder officer: Chief Financial Officer 30930 RUSSELL RANCH ROAD, SUITE 300, WESTLAKE VILLAGE CA 91362
Burkhard Blank officer: EVP Chief Medical Officer C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Lauren M Sabella officer: EVP Chief Operating Officer C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Sanjay R Singh officer: EVP Technical Operations 1 CASPER STREET, DANBURY CT 06810
Alejandro Galindo officer: Chief Commercial Officer 30930 RUSSELL RANCH RD, STE 300, WESTLAKE VILLAGE CA 91362
Stuart A Tross officer: Corp VP, Chief People Officer ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Anthony C Hooper director AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Jennifer Grancio director 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA 91362
Christine Mundkur director
Sabrina Kay director 30930 RUSSELL RANCH ROAD, SUITE 300, WESTLAKE VILLAGE CA 91362
David M Kendall officer: Chief Medical Officer 30930 RUSSELL RANCH ROAD, WESTLAKE VILLAGE CA 91362
Patrick Mccauley officer: Chief Commercial Officer 30930 RUSSELL RANCH ROAD, SUITE 300, WESTLAKE VILLAGE CA 91362
Barton Courtney officer: Chief Compliance Officer 30930 RUSSELL RANCH ROAD, WESTLAKE VILLAGE CA 91362